The FDA recently approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. The approval was based on EV-201, a phase 2 trial in which enfortumab vedotin produced a high rate of response in patients with locally advanced or m...

The FDA has approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, with or without papillary tumors. Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is indicated for patients who are ineligible for or have elected not to receive radical cystectomy and who do not respond to bacillus Calmette-Guérin (BCG) therapy.The approval was based on Keynote 057 (NCT02625961), a multicenter, single...

​One cycle of chemotherapy with bleomycin, etoposide, and cisplatin (BEP) works just as well as two cycles for the adjuvant treatment of high-risk, stage 1 nonseminomatous or combined germ cell tumors of the testis, report the investigators of a single-arm phase 3 study.Patients with testicular cancer, the most common cancer among American males between the ages of 15 and 35, often present with stage 1 disease. However, many nonseminomas and combined germ cell tumors of the testis have malignant...

​The FDA has approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for patients with locally advanced or metastatic urothelial carcinoma. Enfortumab vedotin is indicated for patients whose disease progressed after prior treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. Enfortumab vedotin targets Nectin-4, a cell adhesion molecule highly expressed in urothelial cancers, and is the first...

Nearly half of adults have used marijuana at some point in their lives, and rates are increasing; among young adults, marijuana usage doubled from 10.5% in 2002 to 21.2% in 2014. Given this widespread usage, the question of marijuana-associated cancer risk is an important one, and it is the subject of a systematic review and meta-analysis now published in JAMA Network Open.Marijuana smoke and tobacco smoke share a number of carcinogens. In addition, tetrahydrocannabinol, marijuana's primary psyc...